---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033065"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T09:39:33.160413+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations

## Summary
- Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.
- Full-year net loss $130.9M ($2.32/share) vs $70.8M loss prior year; revenue $43.3M vs $46.0M.
- DURAVYU Phase 3 wet AMD trials LUGANO (>50% enrolled) and LUCIA on track; enrollment completion H2 2025, topline data 2026.
- Phase 2 VERONA DME trial met endpoints: BCVA +10.3 letters vs +3.0 control; 43% had absence of DME.
- Cash $371M as of Dec 31, 2024; runway into 2027; no equity capital plans for 2025.

## SEC filing metadata
- accession: 0000950170-25-033065
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/0000950170-25-033065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/eypt-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033065
- JSON: https://secwatch.observer/filing/0000950170-25-033065.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.